Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.
To compare the ability of a native and a recombinant preparation of the major outer membrane protein of Chlamydia trachomatis mouse pneumonitis (MoPn; Ct-nMOMP and Ct-rMOMP) to protect against an intranasal (i.n.) challenge, BALB/c mice were vaccinated by the intramuscular (i.m.) and subcutaneous (s.c.) routes using CpG-1826 and Montanide ISA 720 as adjuvants. Animals inoculated i.n. with live elementary bodies (EB) of Chlamydia served as a positive control. Negative control groups were immunized with either Neisseria gonorrhoeae recombinant porin B (Ng-rPorB) or with minimal essential medium (MEM-0). Mice immunized with Ct-rMOMP, Ct-nMOMP and EB developed a strong immune response as shown by high levels of Chlamydia specific antibodies in serum and a strong T-cell lymphoproliferative response. Following the i.n. challenge with 10(4) inclusion forming units (IFU) of C. trachomatis, mice immunized with Ct-nMOMP or Ct-rMOMP lost significantly less weight than the negative control animals immunized with Ng-rPorB or MEM-0 (P<0.05). However, mice vaccinated with the Ct-nMOMP lost less weight than those immunized with the Ct-rMOMP (P<0.05). Mice were euthanized at 10 days following the challenge, their lungs weighed and the number of IFU of Chlamydia determined. Based on the lung weight and number of IFU recovered, significant protection was observed in the groups of mice immunized with both Ct-nMOMP and the Ct-rMOMP (P<0.05). Nevertheless, significantly better protection was achieved with the Ct-nMOMP in comparison with the Ct-rMOMP (P<0.05). In conclusion, vaccination with a preparation of the nMOMP elicited a more robust protection than immunization with rMOMP, suggesting that the conformational structure of MOMP is critical for inducing strong protection.
Sun
Guifeng
G
Department of Pathology and Laboratory Medicine, Medical Sciences, Room D440, University of California, Irvine, CA 92697-4800, United States.
Pal
Sukumar
S
Weiland
Joseph
J
Peterson
Ellena M
EM
de la Maza
Luis M
LM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D001835:Body Weight; D049109:Cell Proliferation; D002690:Chlamydia Infections / Q000276:immunology / Q000517:prevention & control*; D002692:Chlamydia trachomatis / Q000276:immunology*; D015169:Colony Count, Microbial; D004247:DNA / Q000008:administration & dosage / Q000494:pharmacology; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D008168:Lung / Q000382:microbiology / Q000473:pathology; D008353:Mannitol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D009829:Oleic Acids / Q000008:administration & dosage / Q000494:pharmacology; D009838:Oligodeoxyribonucleotides; D011014:Pneumonia / Q000276:immunology / Q000517:prevention & control*; D018272:Porins / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; C423449:CpG ODN 1826; D009829:Oleic Acids; D009838:Oligodeoxyribonucleotides; D018272:Porins; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; C071677:omp1 protein, Chlamydia trachomatis; C001681:mannide monooleate; D008353:Mannitol; D004247:DNA